On February 1, 2018 Amgen (NASDAQ:AMGN) reported financial results for the fourth quarter and full year 2017 (Press release, Amgen, FEB 1, 2018, View Source;p=RssLanding&cat=news&id=2329888 [SID1234523700]). Key results include:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
For the fourth quarter, total revenues decreased 3 percent versus the fourth quarter of 2016 to $5.8 billion. For the full year, total revenues decreased 1 percent to $22.8 billion.
GAAP loss per share of $5.89 for the fourth quarter and GAAP earnings per share (EPS) of $2.69 for the full year include a $6.1 billion charge related to impacts of U.S. corporate tax reform.
Non-GAAP EPS were flat in the fourth quarter at $2.89. Non-GAAP EPS increased 8 percent for the full year to $12.58, driven by higher operating margins and interest income and a lower share count.
Free cash flow for the full year grew 9 percent to $10.5 billion, driven by higher operating income and favorable changes in working capital. At year end, cash and investments totaled $41.7 billion.
The Company expects to increase investments to drive additional volume-driven growth of novel medicines in large patient populations. These plans include a new U.S. manufacturing plant.
Cash returned to shareholders totaled $6.5 billion in 2017 through dividends and share repurchases. The Company’s Board of Directors authorized an additional $10 billion of share repurchases. This authorization is in addition to the existing $4.4 billion in share repurchase authorization as of Dec. 31, 2017.
2018 total revenues guidance of $21.8-$22.8 billion; EPS guidance of $11.18-$12.36 on a GAAP basis and $12.60-$13.70 on a non-GAAP basis.
"With strong volume-driven growth for our recently launched products and a promising new product pipeline, we are well positioned for future growth," said Robert A. Bradway, chairman and chief executive officer. "We expect several developments to provide an additional boost for these products, most notably the recent inclusion of cardiovascular outcomes data in the Repatha (evolocumab) prescribing information."
$Millions, except EPS and percentages
Q4’17
Q4’16
YOY Δ
FY ’17
FY ’16
YOY Δ
Total Revenues
$ 5,802
$ 5,965
(3%)
$ 22,849
$ 22,991
(1%)
GAAP Operating Income
$ 2,245
$ 2,485
(10%)
$ 9,973
$ 9,794
2%
GAAP Net (Loss) Income
$ (4,264)
$ 1,935
*
$ 1,979
$ 7,722
(74%)
GAAP (Loss) Earnings Per Share
$ (5.89)
$ 2.59
*
$ 2.69
$ 10.24
(74%)
Non-GAAP Operating Income
$ 2,555
$ 2,859
(11%)
$ 11,658
$ 11,446
2%
Non-GAAP Net Income
$ 2,104
$ 2,160
(3%)
$ 9,246
$ 8,785
5%
Non-GAAP EPS
$ 2.89
$ 2.89
0%
$ 12.58
$ 11.65
8%
* Change in excess of 100%
References in this release to "non-GAAP" measures, measures presented "on a non-GAAP basis" and to "free cash flow" (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations.
Product Sales Performance
Total product sales decreased 2 percent for the fourth quarter of 2017 versus the fourth quarter of 2016. Product sales were flat for the full year.
Repatha sales increased 69 percent for the fourth quarter and 126 percent for the full year driven by higher unit demand.
BLINCYTO (blinatumomab) sales increased 59 percent for the fourth quarter and 52 percent for the full year driven by higher unit demand and, to a lesser extent, net selling price.
Prolia (denosumab) sales increased 24 percent for the fourth quarter and 20 percent for the full year driven by higher unit demand.
KYPROLIS (carfilzomib) sales increased 24 percent for the fourth quarter and 21 percent for the full year driven by higher unit demand.
Vectibix (panitumumab) sales increased 11 percent for the fourth quarter and 5 percent for the full year driven by higher unit demand.
Nplate (romiplostim) sales increased 10 percent for the fourth quarter and the full year driven by higher unit demand.
XGEVA (denosumab) sales increased 4 percent for the fourth quarter driven by higher unit demand, favorable changes in inventory levels and net selling price. Sales increased 3 percent for the full year driven primarily by higher unit demand.
Sensipar/Mimpara (cinacalcet) sales were flat for the fourth quarter as higher net selling price was offset by unfavorable changes in inventory levels. Sales increased 9 percent for the full year driven by net selling price and, to a lesser extent, higher unit demand.
Neulasta (pegfilgrastim) sales were flat for the fourth quarter as lower unit demand was offset by favorable changes in accounting estimates. Sales decreased 2 percent for the full year driven by lower unit demand offset partially by net selling price.
Aranesp (darbepoetin alfa) sales decreased 7 percent for the fourth quarter driven primarily by lower unit demand, favorable prior year changes in accounting estimates and unfavorable changes in foreign exchange rates. Sales decreased 2 percent for the full year as unfavorable changes in foreign exchange rates were offset partially by higher unit demand.
Enbrel (etanercept) sales decreased 13 percent for the fourth quarter and 9 percent for the full year driven by lower unit demand and net selling price.
EPOGEN (epoetin alfa) sales decreased 15 percent for the fourth quarter and the full year driven primarily by lower net selling price.
NEUPOGEN (filgrastim) sales decreased 27 percent for the fourth quarter and 28 percent for the full year driven by lower unit demand.
Product Sales Detail by Product and Geographic Region
$Millions, except percentages
Q4’17
Q4’16
YOY Δ
US
ROW
TOTAL
TOTAL
TOTAL
Repatha
$70
$28
$98
$58
69%
BLINCYTO
29
17
46
29
59%
Prolia
369
205
574
463
24%
KYPROLIS
150
77
227
183
24%
Vectibix
63
96
159
143
11%
Nplate
100
65
165
150
10%
XGEVA
285
106
391
376
4%
Sensipar / Mimpara
322
91
413
411
0%
Neulasta
969
145
1,114
1,116
0%
Aranesp
263
228
491
526
(7%)
Enbrel
1,368
55
1,423
1,644
(13%)
EPOGEN
270
0
270
316
(15%)
NEUPOGEN
82
44
126
173
(27%)
Other*
13
59
72
75
(4%)
Total product sales
$4,353
$1,216
$5,569
$5,663
(2%)
* Other includes Bergamo, MN Pharma, IMLYGIC, Corlanor, and Parsabiv
$Millions, except percentages
FY’17
FY’16
YOY Δ
US
ROW
TOTAL
TOTAL
TOTAL
Repatha
$225
$94
$319
$141
*
BLINCYTO
114
61
175
115
52%
Prolia
1,272
696
1,968
1,635
20%
KYPROLIS
562
273
835
692
21%
Nplate
392
250
642
584
10%
Sensipar / Mimpara
1,374
344
1,718
1,582
9%
Vectibix
251
391
642
611
5%
XGEVA
1,157
418
1,575
1,529
3%
Aranesp
1,114
939
2,053
2,093
(2%)
Neulasta
3,931
603
4,534
4,648
(2%)
Enbrel
5,206
227
5,433
5,965
(9%)
EPOGEN
1,096
0
1,096
1,282
(15%)
NEUPOGEN
369
180
549
765
(28%)
Other**
68
188
256
250
2%
Total product sales
$17,131
$4,664
$21,795
$21,892
0%
* Change in excess of 100%
** Other includes Bergamo, MN Pharma, IMLYGIC, Corlanor, and Parsabiv
Operating Expense, Operating Margin and Tax Rate Analysis
On a GAAP basis:
Total Operating Expenses increased 2 percent in the fourth quarter and decreased 2 percent for the full year, with all expense categories reflecting savings from our transformation and process improvement efforts. Cost of Sales margin was unfavorable by 0.2 percentage points in the fourth quarter driven primarily by expenses related to Hurricane Maria in Puerto Rico, unfavorable product mix and other inventory costs, offset partially by lower amortization of intangible assets and royalties. For the full year, Cost of Sales margin improved 0.3 percentage points driven primarily by lower amortization of intangible assets, lower royalties and favorable manufacturing costs, offset partially by expenses related to Hurricane Maria, unfavorable product mix and other inventory costs. Research & Development (R&D) expenses decreased 3 percent for the fourth quarter and 7 percent for the full year driven primarily by lower spending required to support certain later-stage clinical programs and lower external business development expenses. Selling, General & Administrative (SG&A) expenses increased 8 percent in the fourth quarter due to investments in product launches and marketed product support, offset partially by the expiration of ENBREL residual royalty payments. For the full year, SG&A expenses decreased 4 percent due to the expiration of ENBREL residual royalty payments, offset partially by investments in product launches and marketed product support. Other expenses increased for the full year due primarily to net charges related to the Company’s decision to discontinue internal development of AMG 899 in Q3 2017.
Operating Margin decreased by 3.6 percentage points in the fourth quarter to 40.3 percent, and improved by 1.1 percentage points for the full year to 45.8 percent.
Tax Rate increased in the fourth quarter and full year due to the impacts of U.S. corporate tax reform.
On a non-GAAP basis:
Total Operating Expenses increased 5 percent in the fourth quarter and decreased 3 percent for the full year, with all expense categories reflecting savings from our transformation and process improvement efforts. Cost of Sales margin was unfavorable by 1.4 percentage points in the fourth quarter driven primarily by expenses related to Hurricane Maria in Puerto Rico, unfavorable product mix and other inventory costs, offset partially by lower royalties. For the full year, Cost of Sales margin was unfavorable by 0.2 percentage points driven primarily by expenses related to Hurricane Maria, unfavorable product mix and other inventory costs, offset partially by lower royalties and favorable manufacturing costs. R&D expenses decreased 3 percent for the fourth quarter and 7 percent for the full year driven primarily by lower spending required to support certain later-stage clinical programs and lower external business development expenses. SG&A expenses increased 8 percent in the fourth quarter due to investments in product launches and marketed product support, offset partially by the expiration of ENBREL residual royalty payments. For the full year, SG&A expenses decreased 2 percent due to the expiration of ENBREL residual royalty payments, offset partially by investments in product launches and marketed product support.
Operating Margin decreased by 4.6 percentage points in the fourth quarter to 45.9 percent, and improved by 1.2 percentage points for the full year to 53.5 percent.
Tax Rate for the fourth quarter decreased 2.1 percentage points due primarily to favorable changes in the geographic mix of earnings. The full year tax rate decreased 0.8 percentage points driven by changes in the geographic mix of earnings, offset partially by lower tax benefits from share-based compensation payments.
$Millions, except percentages
GAAP
Non-GAAP
Q4’17
Q4’16
YOY Δ
Q4’17
Q4’16
YOY Δ
Cost of Sales
$1,059
$1,067
(1%)
$816
$753
8%
% of product sales
19.0%
18.8%
0.2 pts.
14.7%
13.3%
1.4 pts.
Research & Development
$1,043
$1,078
(3%)
$1,025
$1,056
(3%)
% of product sales
18.7%
19.0%
(0.3) pts.
18.4%
18.6%
(0.2) pts.
Selling, General & Administrative
$1,427
$1,323
8%
$1,406
$1,297
8%
% of product sales
25.6%
23.4%
2.2 pts.
25.2%
22.9%
2.3 pts.
Other
$28
$12
*
$0
$0
NM
TOTAL Operating Expenses
$3,557
$3,480
2%
$3,247
$3,106
5%
Operating Margin
operating income as a % of product sales
40.3%
43.9%
(3.6) pts.
45.9%
50.5%
(4.6) pts.
Tax Rate
292.6%
15.2%
277.4 pts.
16.6%
18.7%
(2.1) pts.
* Change in excess of 100%
NM: Not Meaningful
pts: percentage points
$Millions, except percentages
GAAP
Non-GAAP
FY’17
FY’16
YOY Δ
FY’17
FY’16
YOY Δ
Cost of Sales
$4,069
$4,162
(2%)
$2,943
$2,913
1%
% of product sales
18.7%
19.0%
(0.3) pts.
13.5%
13.3%
0.2 pts.
Research & Development
$3,562
$3,840
(7%)
$3,482
$3,755
(7%)
% of product sales
16.3%
17.5%
(1.2) pts.
16.0%
17.2%
(1.2) pts.
Selling, General & Administrative
$4,870
$5,062
(4%)
$4,766
$4,877
(2%)
% of product sales
22.3%
23.1%
(0.8) pts.
21.9%
22.3%
(0.4) pts.
Other
$375
$133
*
$0
$0
NM
TOTAL Operating Expenses
$12,876
$13,197
(2%)
$11,191
$11,545
(3%)
Operating Margin
operating income as a % of product sales
45.8%
44.7%
1.1 pts.
53.5%
52.3%
1.2 pts.
Tax Rate
79.4%
15.7%
63.7 pts.
18.0%
18.8%
(0.8) pts.
* Change in excess of 100%
NM: Not Meaningful
pts: percentage points
Cash Flow and Balance Sheet
The Company generated $2.9 billion of free cash flow in the fourth quarter of 2017, flat versus the fourth quarter of 2016. The Company generated $10.5 billion of free cash flow for the full year versus $9.6 billion in 2016 driven by higher operating income and favorable changes in working capital.
The Company’s first quarter 2018 dividend of $1.32 per share declared on Dec. 12, 2017, will be paid on March 8, 2018, to all stockholders of record as of Feb. 15, 2018. This represents a 15 percent increase from that paid in each of the previous four quarters.
During the fourth quarter, the Company repurchased 4.5 million shares of common stock at a total cost of $0.8 billion. For the full year, the Company repurchased 18.5 million shares of common stock at a total cost of $3.1 billion. In January 2018, the Company’s Board of Directors authorized an additional $10 billion of share repurchases. This authorization is in addition to the existing $4.4 billion in share repurchase authorization as of Dec. 31, 2017.
$Billions, except shares
Q4’17
Q4’16
YOY Δ
FY’17
FY’16
YOY Δ
Operating Cash Flow
$3.0
$3.1
($0.1)
$11.2
$10.4
$0.8
Capital Expenditures
0.2
0.2
(0.1)
0.7
0.7
(0.1)
Free Cash Flow
2.9
2.9
0.0
10.5
9.6
0.9
Dividends Paid
0.8
0.7
0.1
3.4
3.0
0.4
Share Repurchase
0.8
1.0
(0.2)
3.1
3.0
0.1
Avg. GAAP Diluted Shares (millions)
724
748
(24)
735
754
(19)
Avg. Non-GAAP Diluted Shares (millions)
729
748
(19)
735
754
(19)
Cash and Investments
41.7
38.1
3.6
41.7
38.1
3.6
Debt Outstanding
35.3
34.6
0.7
35.3
34.6
0.7
Stockholders’ Equity
25.2
29.9
(4.6)
25.2
29.9
(4.6)
Note: Numbers may not add due to rounding
Additional Capital Investments in the United States
The Company expects to invest approximately $3.5 billion in capital expenditures over the next five years, with approximately 75 percent of that investment in the U.S., up from about 50 percent in recent years. This investment includes committing up to $300 million to build a new manufacturing plant in the U.S. The new facility will employ Amgen’s proven next-generation biomanufacturing capabilities, and manufacture products for the U.S. and export markets. Next-generation biomanufacturing requires less time and capital investment to build than a traditional biomanufacturing plant and is less costly to operate, with less environmental impact. The construction and validation work is expected to add 220 jobs to the local economy. In addition, Amgen expects this new facility to employ up to 300 highly skilled full-time employees. Amgen expects to finalize the exact location in the second quarter. The Company is also increasing the size of the Amgen Ventures fund, providing up to $300 million of growth capital for early-stage, innovative biotechnology companies in the U.S.
2018 Guidance
For the full year 2018, the Company expects:
Total revenues in the range of $21.8 billion to $22.8 billion.
On a GAAP basis, EPS in the range of $11.18 to $12.36 and a tax rate in the range of 13 percent to 14 percent.
On a non-GAAP basis, EPS in the range of $12.60 to $13.70 and a tax rate in the range of 14 percent to 15 percent.
Capital expenditures to be approximately $750 million.
Fourth Quarter Product and Pipeline Update
Key development milestones:
Clinical Program
Indication
Projected Milestone
KYPROLIS
Relapsed or refractory multiple myeloma
EU regulatory review (ENDEAVOR OS data)
Regulatory reviews (ASPIRE OS data)
BLINCYTO
Acute lymphoblastic leukemia
EU regulatory review (TOWER OS data)
Regulatory reviews (MRD-positive)
XGEVA
Prevention of SREs in multiple myeloma
EU regulatory review
Prolia
Glucocorticoid-induced osteoporosis
U.S. regulatory review
EVENITY(romosozumab)
Postmenopausal osteoporosis
U.S. regulatory resubmission
EU regulatory review
Aimovig (erenumab)
Migraine prevention
U.S. regulatory review
ABP 710
(biosimilar infliximab)
Oncology
Phase 3 data
ABP 980
(biosimilar trastuzumab)
Oncology
Regulatory reviews
OS = overall survival; MRD = minimal residual disease; SRE = skeletal-related event
The Company provided the following updates on selected product and pipeline programs:
Repatha
Repatha is the first and only PCSK9 inhibitor approved to prevent heart attacks, strokes and coronary revascularizations in adults with established cardiovascular disease.
In December, the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (sBLA) to include data from the Phase 3 Repatha cardiovascular outcomes study in the prescribing information (PI).
The FDA also approved Repatha to be used as an adjunct to diet, alone or in combination with other lipid-lowering therapies, such as statins, for the treatment of adults with primary hyperlipidemia to lower LDL-C.
Tezepelumab
In December, patients began enrolling in a Phase 3 study to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe uncontrolled asthma.
Aimovig
In January, a Phase 3b study met its primary endpoint and all secondary endpoints in patients with episodic migraine who had experienced two to four previous preventive treatment failures due to lack of efficacy or intolerable side effects.
KYPROLIS
In January, the FDA approved a supplemental New Drug Application (sNDA) to include OS data from the Phase 3 head-to-head ENDEAVOR study in the PI.
In January, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending a label variation to include updated OS data from the Phase 3 head-to-head ENDEAVOR study in patients with relapsed or refractory multiple myeloma.
In December, the Company submitted an sNDA to the FDA and a variation to the marketing authorization to the EMA to include the OS data from the ASPIRE study in the product labeling.
XGEVA
In January, the FDA approved an sBLA to expand the currently approved indication to include the prevention of SREs in patients with multiple myeloma.
A Phase 3 study of XGEVA as an experimental adjuvant treatment for women with high-risk, early stage breast cancer receiving standard of care neoadjuvant or adjuvant cancer therapy did not meet its primary endpoint of bone metastasis-free survival.
Nplate
In January, the European Commission (EC) approved an expanded indication to include the treatment of chronic immune (idiopathic) thrombocytopenic purpura in patients one year of age and older who are refractory to other treatments.
BLINCYTO
In December, the Company announced that the FDA accepted for priority review an sBLA for the treatment of MRD in patients with acute lymphoblastic leukemia (ALL). The Prescription Drug User Fee Act target action date is March 29, 2018.
In January, the CHMP of the EMA adopted a positive opinion recommending a label variation to include OS data from the Phase 3 TOWER study, supporting the conversion of the conditional marketing authorization to a full marketing authorization in adult patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.
EVENITY
In January, the Company announced that the EMA accepted the Marketing Authorization Application (MAA) for EVENITY for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture.
MVASI (biosimilar bevacizumab)
In January, the EC granted marketing authorization for MVASI, a biosimilar to Avastin, for the treatment of certain types of cancer.
EVENITY and Aimovig trade names provisionally approved by FDA
EVENITY is developed in collaboration with UCB globally, as well as our joint venture partner Astellas in Japan
Tezepelumab is developed in collaboration with AstraZeneca
Aimovig is developed in collaboration with Novartis
Avastin is a registered trademark of Genentech
Non-GAAP Financial Measures
In this news release, management has presented its operating results for the fourth quarters and full years of 2017 and 2016, in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and on a non-GAAP basis. In addition, management has presented its full year 2018 EPS and tax rate guidance in accordance with GAAP and on a non-GAAP basis. These non-GAAP financial measures are computed by excluding certain items related to acquisitions, restructuring and certain other items, including the repatriation tax on accumulated foreign earnings and other impacts of U.S. corporate tax reform, from the related GAAP financial measures. Reconciliations for these non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the news release. Management has also presented Free Cash Flow (FCF), which is a non-GAAP financial measure, for the fourth quarters and full years of 2017 and 2016. FCF is computed by subtracting capital expenditures from operating cash flow, each as determined in accordance with GAAP.
The Company believes that its presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses certain non-GAAP financial measures to enhance an investor’s overall understanding of the financial performance and prospects for the future of the Company’s ongoing business activities by facilitating comparisons of results of ongoing business operations among current, past and future periods. The Company believes that FCF provides a further measure of the Company’s liquidity.
The Company uses the non-GAAP financial measures set forth in the news release in connection with its own budgeting and financial planning internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. The non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.